A Phase 2 interventional study of Sotorasib in Non-small Cell Lung Cancer, sponsored by Amgen. Terminated at 67 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-13.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing sotorasib in Carcinoma, Non-Small-Cell Lung — 8 open to participants now, 10 under way, 1 of them phase 3. sotorasib · Carcinoma, Non-Small-Cell Lung.
Among the 19 studies testing sotorasib in Carcinoma, Non-Small-Cell Lung, this one is the 5th largest by enrollment, is one of 9 that started in 2022, is one of 10 in phase 2, and was the 2nd registered.
7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →8 of the 19 studies testing sotorasib in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18+
Amgen · Sites in United States, Argentina, Australia and 35 more countries
Ages 18–100
NYU Langone Health · Sites in United States
Ages 18–100
Gustave Roussy, Cancer Campus, Grand Paris · Sites in France
Ages 18+
By country, each count listing its studies:
sotorasib: first FDA approval 2021 (LUMAKRAS), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 14 · Phase 3 1 · Phase 4 1
First in 2021; this study’s year is marked. 9 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 42 is below the median of 62 across 6,028 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 24 across the 19 interventional studies. Of the 5 that completed or were terminated, 2 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 19 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
40 studies in Carcinoma, Non-Small-Cell Lung by Amgen: 2 open now, 7 under way, 4 of them phase 3. Of 27 finished, 13 (48%) have results posted.
Among the 40 studies in Carcinoma, Non-Small-Cell Lung by Amgen, this one is the 23rd largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2022, is one of 14 in phase 2, and was the 31st registered.
Amgen’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 1999.
5 of the studies testing sotorasib in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05920356Phase 3AmgenA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | 2027-06-30 |
| NCT06249282City of Hope Medical CenterCarfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer | 2026-11-24 |
| NCT04625647SWOG Cancer Research NetworkTesting the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) | 2026-12-31 |
| NCT07012031National Cancer Institute (NCI)Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation | 2027-06-14 |
| NCT05815173NYU Langone HealthLadarixin With Sotorasib in Advanced NSCLC | 2027-08 |
Add all 5 to your calendar (.ics) → With an account.
Among the 19 studies testing sotorasib in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 40 in Carcinoma, Non-Small-Cell Lung:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main objective of this study is to evaluate the tumor objective response rate (ORR) assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria in participants who receive sotorasib at either 960 mg daily or 240 mg daily whose tumors are programmed death-ligand 1 (PD-L1) Tumor Proportion Score (TPS) \< 1% and/or harbor a serine/threonine kinase 11 (STK11) co-mutation, in a subgroup of participants with PD-L1 \< 1% and in a subgroup of participants with STK11 co-mutation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with metastatic non-small cell lung cancer (NSCLC) with Kirsten rat sarcoma (KRAS) p.G12C mutation whose tumors express \< 1% programmed death-ligand 1 (PD-L1) and/or serine/threonine kinase 11 (STK11) mutation in need of first line treatment will be administered sotorasib 960 mg daily. Participants will be stratified by known presence of STK11 mutation.
Drug: Sotorasib
Participants with metastatic non-small cell lung cancer (NSCLC) with Kirsten rat sarcoma (KRAS) p.G12C mutation whose tumors express \< 1% programmed death-ligand 1 (PD-L1) and/or serine/threonine kinase 11 (STK11) mutation in need of first line treatment will be administered sotorasib 240 mg daily. Participants will be stratified by known presence of STK11 mutation.
Drug: Sotorasib
Oral tablet
Also known as: AMG 510, LUMYKRAS, LUMAKRAS
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)
Objective response was defined as best overall response (BOR) of complete response (CR) or partial response (PR), as defined by RECIST 1.1. CR was defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR was defined as at least a 30% decrease in the sum of diameter (SOD) of target lesions, taking as reference the baseline sum diameters. Progressive disease (PD) was defined as at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. Responses were assessed based on BICR.
Time frame: From the first dose of trial drug until min (last dose + 30 days, end of trial [EOT]); median [min, max] duration was 5.32 [0.8, 30.9] months
Disease Control Rate (DCR) Per RECIST Version 1.1 as Assessed by BICR
DCR was defined as the percentage of participants with an OR or stable disease (SD) per RECIST v1.1. CR: disappearance of all target lesions. All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis to \<10 mm. PR: at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of the longest diameter. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD: at least a 20% increase in sum of diameters of target lesions, taking as reference the smallest sum on study (this includes baseline sum if that is the smallest on study).
Time frame: From randomization until EOT; median [min, max] time on trial was 9.72 [0.8, 38.0] months
Duration of Response (DOR) Per RECIST Version 1.1 as Assessed by BICR
DOR was defined as time from the first documentation of OR subsequently confirmed until the first documentation of PD or death due to any cause, whichever comes first. CR: disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (target or non-target) must have a reduction in their short axis \<10 mm. PR: at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. PD: at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.
Time frame: From randomization until EOT; median [min, max] time on trial was 9.72 [0.8, 38.0] months
Time to Response (TTR) Per RECIST Version 1.1 as Assessed by BICR
TTR was defined as time from first dose date to the first documentation of PR or CR subsequently confirmed. CR was defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. PD was defined as at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.
Time frame: From randomization until EOT; median [min, max] time on trial was 9.72 [0.8, 38.0] months
Progression-free Survival (PFS) as Assessed by BICR
PFS by BICR was defined as the time from first dose date to disease progression or death due to any cause (whichever comes first). PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the baseline SOD of target lesions.
Time frame: From randomization until EOT; median [min, max] time on trial was 9.72 [0.8, 38.0] months
Overall Survival (OS)
OS was defined as the time from first dose date until event of death due to any cause.
Time frame: From randomization until EOT; median [min, max] time on trial was 9.72 [0.8, 38.0] months
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-related TEAEs
TEAEs are AEs starting on or after the first dose of sotorasib as determined by the flag indicating if the AE started prior to the first dose on the Events case report form (CRF) and up to and including 30 days after the last dose of sotorasib or the EOT date, whichever is earlier. A treatment-related TEAE is any TEAE with the relationship flag on the events CRF indicating there is a reasonable possibility that the event may have been caused by investigational medicinal product. Clinically significant changes in vital signs, electrocardiograms (ECGs), and clinical laboratory tests were included as TEAEs.
Time frame: From the first dose of trial drug until min (last dose + 30 days, EOT); median [min, max] duration was 5.32 [0.8, 30.9] months
Plasma Concentration of Sotorasib
Blood samples were collected at specified timepoints.
Time frame: Cycles 1 and 2: Day 1 pre-dose and 1 hour post-dose; Cycles 3, 4 and, 5: Day 1 pre-dose (cycle length = 21 days)
A total of 42 participants were enrolled across 17 trial centers in the United States and Europe from January 2022 to May 2025.
| Milestone | Sotorasib 240 mg | Sotorasib 960 mg |
|---|---|---|
| Started | 21 | 21 |
| Completed | 0 | 0 |
| Not completed | 21 | 21 |
| Withdrew: Withdrawal of consent from trial | 4 | 0 |
| Withdrew: Decision by sponsor | 2 | 5 |
| Withdrew: Death | 15 | 16 |
Objective response was defined as best overall response (BOR) of complete response (CR) or partial response (PR), as defined by RECIST 1.1. CR was defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR was defined as at least a 30% decrease in the sum of diameter (SOD) of target lesions, taking as reference the baseline sum diameters. Progressive disease (PD) was defined as at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. Responses were assessed based on BICR.
| percentage of participants | Sotorasib |
|---|---|
| Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) | 26.8 (14.2 to 42.9) |
DCR was defined as the percentage of participants with an OR or stable disease (SD) per RECIST v1.1. CR: disappearance of all target lesions. All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis to \<10 mm. PR: at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of the longest diameter. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD: at least a 20% increase in sum of diameters of target lesions, taking as reference the smallest sum on study (this includes baseline sum if that is the smallest on study).
| percentage of participants | Sotorasib |
|---|---|
| Disease Control Rate (DCR) Per RECIST Version 1.1 as Assessed by BICR | 73.2 (57.1 to 85.8) |
DOR was defined as time from the first documentation of OR subsequently confirmed until the first documentation of PD or death due to any cause, whichever comes first. CR: disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (target or non-target) must have a reduction in their short axis \<10 mm. PR: at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. PD: at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.
| months | Sotorasib |
|---|---|
| Duration of Response (DOR) Per RECIST Version 1.1 as Assessed by BICR | 7.2 (2.8 to NA) |
TTR was defined as time from first dose date to the first documentation of PR or CR subsequently confirmed. CR was defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. PD was defined as at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.
| months | Sotorasib |
|---|---|
| Time to Response (TTR) Per RECIST Version 1.1 as Assessed by BICR | 1.5 (1 to 6) |
PFS by BICR was defined as the time from first dose date to disease progression or death due to any cause (whichever comes first). PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the baseline SOD of target lesions.
| months | Sotorasib |
|---|---|
| Progression-free Survival (PFS) as Assessed by BICR | 4.5 (2.7 to 8.3) |
OS was defined as the time from first dose date until event of death due to any cause.
| months | Sotorasib |
|---|---|
| Overall Survival (OS) | 11.8 (7.7 to 16.4) |
TEAEs are AEs starting on or after the first dose of sotorasib as determined by the flag indicating if the AE started prior to the first dose on the Events case report form (CRF) and up to and including 30 days after the last dose of sotorasib or the EOT date, whichever is earlier. A treatment-related TEAE is any TEAE with the relationship flag on the events CRF indicating there is a reasonable possibility that the event may have been caused by investigational medicinal product. Clinically significant changes in vital signs, electrocardiograms (ECGs), and clinical laboratory tests were included as TEAEs.
| count of participants | Sotorasib 240 mg | Sotorasib 960 mg |
|---|---|---|
| TEAEs | 19 | 21 |
| Treatment-related TEAEs | 13 | 11 |
Blood samples were collected at specified timepoints.
| ng/mL | Sotorasib 240 mg QD | Sotorasib 960 mg QD |
|---|---|---|
| Cycle 1 Day 1 pre-dose | 0.00 ± 0.00 | 0.00 ± 0.00 |
| Cycle 1 Day 1: 1 hour | 6840 ± 4060 | 11600 ± 6880 |
| Cycle 2 Day 1 pre-dose | 394 ± 858 | 883 ± 2140 |
| Cycle 2 Day 1: 1 hour | 4870 ± 3200 | 7340 ± 3760 |
| Cycle 3 Day 1: pre-dose | 347 ± 698 | 259 ± 331 |
| Cycle 4 Day 1: pre-dose | 366 ± 590 | 255 ± 277 |
| Cycle 5 Day 1: pre-dose | 211 ± 353 | 164 ± 153 |
Collected over For mortality reporting: from randomization until EOT; median [min, max] time on trial was 9.72 [0.8, 38.0] months. For AE reporting: from the first dose of trial drug until min(last dose + 30 days, EOT); median [min, max] duration was 5.32 [0.8, 30.9] months.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sotorasib 240 mg | 15/21 (71.4%) | 9/21 (42.9%) | 18/21 (85.7%) |
| Sotorasib 960 mg | 16/21 (76.2%) | 9/21 (42.9%) | 20/21 (95.2%) |
| Event | Sotorasib 240 mg | Sotorasib 960 mg |
|---|---|---|
| General physical health deteriorationGeneral disorders | 0/21 | 2/21 |
| PneumoniaInfections and infestations | 2/21 | 0/21 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/21 | 2/21 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/21 | 2/21 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/21 | 2/21 |
| AnaemiaBlood and lymphatic system disorders | 1/21 | 0/21 |
| Iron deficiency anaemiaBlood and lymphatic system disorders | 0/21 | 1/21 |
| Acute cardiac eventCardiac disorders | 0/21 | 1/21 |
| Atrial fibrillationCardiac disorders | 0/21 | 1/21 |
| Cardiac failureCardiac disorders | 1/21 | 0/21 |
| Event | Sotorasib 240 mg | Sotorasib 960 mg |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 7/21 | 7/21 |
| Chest painGeneral disorders | 2/21 | 6/21 |
| NauseaGastrointestinal disorders | 3/21 | 5/21 |
| VomitingGastrointestinal disorders | 4/21 | 1/21 |
| FatigueGeneral disorders | 4/21 | 2/21 |
| Back painMusculoskeletal and connective tissue disorders | 3/21 | 4/21 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 4/21 | 2/21 |
| Productive coughRespiratory, thoracic and mediastinal disorders | 1/21 | 4/21 |
| AnaemiaBlood and lymphatic system disorders | 2/21 | 3/21 |
| ConstipationGastrointestinal disorders | 3/21 | 2/21 |
All randomized participants. As per-planned analysis, the data for baseline measures were collected, analyzed and reported as a single cohort.
| Age, Continuous(years) | Sotorasib |
|---|---|
| Mean | 66.5 ± 9.8 |
| Sex: Female, Male(Participants) | Sotorasib |
|---|---|
| Female | 13 |
| Male | 29 |
| Race/Ethnicity, Customized(Participants) | Sotorasib |
|---|---|
| White | 41 |
| Other | 1 |
| Race/Ethnicity, Customized(Participants) | Sotorasib |
|---|---|
| Not Hispanic or Latino | 42 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Ran from Jan 2022 to primary completion in May 2025, 40 months.
Results were first posted in Jul 2026, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sotorasib
Carcinoma, Non-Small-Cell Lung →